Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Seelos Therapeutics Inc (SEEL)

Seelos Therapeutics Inc (SEEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 145
  • Shares Outstanding, K 372
  • Annual Sales, $ 2,200 K
  • Annual Income, $ -37,880 K
  • EBIT $ -30 M
  • EBITDA $ -29 M
  • 60-Month Beta 1.94
  • Price/Sales 0.09
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1,099.95
  • Most Recent Earnings $1.92 on 08/14/24
  • Next Earnings Date 11/19/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3700 +5.41%
on 11/18/24
1.3400 -70.90%
on 10/25/24
-0.6200 (-61.39%)
since 10/18/24
3-Month
0.3700 +5.41%
on 11/18/24
8.8576 -95.60%
on 09/24/24
-6.5012 (-94.34%)
since 08/16/24
52-Week
0.3700 +5.41%
on 11/18/24
698.8800 -99.94%
on 11/22/23
-485.3700 (-99.92%)
since 11/17/23

Most Recent Stories

More News
Seelos: Q2 Earnings Snapshot

Seelos: Q2 Earnings Snapshot

SEEL : 0.3900 (-27.79%)
This May be One of the Biggest Catalysts for Psychedelic Stocks in 2024

About 43.8 million adults in the U.S. experience a mental health issue in a given year, according to the National Institute of Mental Health (NAMI). Nearly 16 million of those adults live with major depression....

CMPS : 4.41 (-0.90%)
SEEL : 0.3900 (-27.79%)
ATAI : 1.6100 (+5.92%)
MNMD : 7.56 (+6.63%)
NUMI.TO : 0.0450 (-10.00%)
NUMIF : 0.0321 (-2.73%)
Breaking: The US FDA Just Granted Priority Review of an MDMA Treatment for PTSD

At the moment, about 14 million people live with PTSD just in the U.S. Unfortunately, despite extensive clinical research, PTSD is still a significant unmet medical need. However, that may soon change...

CMPS : 4.41 (-0.90%)
SEEL : 0.3900 (-27.79%)
ATAI : 1.6100 (+5.92%)
MNMD : 7.56 (+6.63%)
NUMI.TO : 0.0450 (-10.00%)
NUMIF : 0.0321 (-2.73%)
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

CYBN.NE : 13.5500 (-4.24%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 9.82 (-3.35%)
ATAI : 1.6100 (+5.92%)
MNMD : 7.56 (+6.63%)
SEEL : 0.3900 (-27.79%)
CMPS : 4.41 (-0.90%)
Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease

/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for...

SEEL : 0.3900 (-27.79%)
Stock Index Futures Plunge on Fed’s Hawkish Stance, BoE Decision in Focus

December S&P 500 futures (ESZ23) are down -0.42%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.65% this morning as Treasury yields jumped after the Federal Reserve signaled interest rates...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
NVDA : 141.95 (-3.22%)
MSFT : 417.00 (+1.00%)
CHWY : 34.89 (-2.73%)
WDC : 66.43 (+0.83%)
COTY : 7.32 (+1.81%)
JD-.LN : 93.460 (-2.07%)
FDX : 299.97 (+1.63%)
ULCC : 5.60 (+0.90%)
HQY : 104.25 (-0.38%)
TRNS : 109.02 (+2.09%)
Seelos Therapeutics Provides Second Quarter 2023 Clinical Update

- Seelos expects to release top-line data in its registration directed study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior...

SEEL : 0.3900 (-27.79%)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END

CYBN.NE : 13.5500 (-4.24%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 9.82 (-3.35%)
CMPS : 4.41 (-0.90%)
SEEL : 0.3900 (-27.79%)
MNMD : 7.56 (+6.63%)
NUMIF : 0.0321 (-2.73%)
NUMI.TO : 0.0450 (-10.00%)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

/PRNewswire/ -- Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise...

NUMI.TO : 0.0450 (-10.00%)
CYBN : 9.82 (-3.35%)
CMPS : 4.41 (-0.90%)
MNMD : 7.56 (+6.63%)
SEEL : 0.3900 (-27.79%)
NUMIF : 0.0321 (-2.73%)
Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results

/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for...

SEEL : 0.3900 (-27.79%)

Business Summary

Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which...

See More

Key Turning Points

3rd Resistance Point 0.5967
2nd Resistance Point 0.5473
1st Resistance Point 0.4687
Last Price 0.3900
1st Support Level 0.3407
2nd Support Level 0.2913
3rd Support Level 0.2127

See More

52-Week High 698.8800
Fibonacci 61.8% 432.0492
Fibonacci 50% 349.6250
Fibonacci 38.2% 267.2008
Last Price 0.3900
52-Week Low 0.3700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar